Compare GPMT & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GPMT | INKT |
|---|---|---|
| Founded | 2015 | 2017 |
| Country | United States | United States |
| Employees | 28 | N/A |
| Industry | Real Estate Investment Trusts | Medicinal Chemicals and Botanical Products |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 65.6M | 70.6M |
| IPO Year | N/A | 2021 |
| Metric | GPMT | INKT |
|---|---|---|
| Price | $1.48 | $12.18 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | $3.00 | ★ $35.00 |
| AVG Volume (30 Days) | ★ 144.4K | 30.7K |
| Earning Date | 05-05-2026 | 05-15-2026 |
| Dividend Yield | ★ 12.99% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $458.85 | N/A |
| Revenue Next Year | $8.63 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.24 | $6.80 |
| 52 Week High | $3.12 | $76.00 |
| Indicator | GPMT | INKT |
|---|---|---|
| Relative Strength Index (RSI) | 54.72 | 58.80 |
| Support Level | $1.24 | $10.79 |
| Resistance Level | $1.58 | $12.40 |
| Average True Range (ATR) | 0.07 | 0.88 |
| MACD | 0.02 | 0.13 |
| Stochastic Oscillator | 78.26 | 76.79 |
Granite Point Mortgage Trust Inc focuses on directly originating, investing in, and managing senior floating rate commercial mortgage loans and other debt and debt-like commercial real estate investments. The company constructs its investment portfolio on a loan-by-loan basis, emphasizing rigorous credit underwriting, selectivity, and diversification, and assesses each investment from a fundamental value perspective relative to other opportunities available in the market. It typically provides intermediate-term bridge or transitional financing for a variety of purposes, including acquisitions, recapitalizations, refinancing, and a range of business plans, including lease-up, renovation, repositioning and repurposing of the commercial property.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.